Literature DB >> 26774199

Hydroxyethyl Starch 130/0.4 and the Risk of Acute Kidney Injury After Cardiopulmonary Bypass: A Single-Center Retrospective Study.

Marc-Gilbert Lagny1, Laurence Roediger2, Jean-Noel Koch1, Fanny Dubois3, Marc Senard2, Anne-Françoise Donneau4, Marie Bernard Hubert2, Gregory A Hans5.   

Abstract

OBJECTIVES: To investigate whether using hydroxyethyl starch (HES) 130/0.4 as a pump prime and for intraoperative fluid therapy is associated with postoperative acute kidney injury (AKI) after adult cardiac surgery.
DESIGN: Retrospective observational study.
SETTING: University hospital, single center. PARTICIPANTS: Six hundred six adult patients who underwent on-pump cardiac surgery between April 2013 and June 2014 were included.
INTERVENTIONS: Until July 2013, balanced HES 130/0.4 (Volulyte(®), Fresenius Kabi AG, Bad Homburg, Germany) was used both as a pump prime (1,500 mL) and for intraoperative fluid therapy (1,000 mL). From August 2013, HES was replaced entirely by a balanced crystalloid solution (Plasma-Lyte A, Baxter, Lessines, Belgium).
MEASUREMENTS AND MAIN RESULTS: The primary endpoint was the incidence of postoperative AKI during the first 48 postoperative hours, determined using the Acute Kidney Injury Network classification. Secondary outcomes included kidney function at postoperative day 7, postoperative dialysis or hemofiltration, postoperative pulmonary complications, lengths of intensive care unit and hospital stays, postoperative fluid balance and urinary output, surgical revision for bleeding, and 30-day mortality. Multivariable logistic regression was used to adjust for confounders. AKI occurred in 9.5% of crystalloid patients and in 21.5% of HES patients. Patients who received HES were about twice as likely to develop postoperative AKI as those treated with crystalloids (adjusted OR 2.26; 95% CI, 1.40-3.80; p = 0.02). HES patients also had a significantly more positive fluid balance and a lower urinary output during the first 48 postoperative hours. The incidence of surgical revision for bleeding was greater in the HES group (4.6% v 1.4%, p = 0.02).
CONCLUSION: This study suggested that using balanced HES 130/0.4 as a pump prime and for intraoperative fluid therapy in adult patients undergoing on-pump cardiac surgery was associated with a greater incidence of AKI during the early postoperative period.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HES; acute kidney injury; cardiac surgery; hydroxyethyl starch

Mesh:

Substances:

Year:  2015        PMID: 26774199     DOI: 10.1053/j.jvca.2015.10.010

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  7 in total

1.  The dose of hydroxyethyl starch 6% 130/0.4 for fluid therapy and the incidence of acute kidney injury after cardiac surgery: A retrospective matched study.

Authors:  Mona Momeni; Lompoli Nkoy Ena; Michel Van Dyck; Amine Matta; David Kahn; Dominique Thiry; André Grégoire; Christine Watremez
Journal:  PLoS One       Date:  2017-10-18       Impact factor: 3.240

2.  Effects of hydroxyethyl starch 130/0.4 on the kidney tissue of rats with ureteral obstruction.

Authors:  Işın Güneş; Nuran Süngü; Aydan Kılıçarslan; Volkan Şıvgın; Metin Alkan; Ayşegül Küçük; Hakan Boyunağa; Yusuf Ünal; Mustafa Arslan
Journal:  Drug Des Devel Ther       Date:  2018-09-20       Impact factor: 4.162

3.  Large volume infusions of hydroxyethyl starch during cardiothoracic surgery may be associated with postoperative kidney injury: propensity-matched analysis.

Authors:  Wataru Matsunaga; Masamitsu Sanui; Yusuke Sasabuchi; Yasuma Kobayashi; Asuka Kitajima; Fumitaka Yanase; Yutaka Takisawa; Alan Kawarai Lefor
Journal:  Perioper Med (Lond)       Date:  2019-10-31

4.  The comparison of albumin and 6% hydroxyethyl starches (130/0.4) in cardiac surgery: a meta-analysis of randomized controlled clinical trials.

Authors:  Ling Wei; Dongping Li; Lin Sun
Journal:  BMC Surg       Date:  2021-09-11       Impact factor: 2.102

5.  The effects of hydroxyethyl starch 130/0.4 on perioperative renal function in patients undergoing cardiac surgery: A randomised controlled trial.

Authors:  Kei Nagaya; Akiko Yoshida; Yosuke Ito; Suguru Watanabe; Tadanori Minagawa; Yoshifumi Saijo
Journal:  Ann Med Surg (Lond)       Date:  2022-08-24

6.  Effect of 6% hydroxyethyl starch 130/0.4 on kidney and haemostatic function in cardiac surgical patients: a randomised controlled trial.

Authors:  A E Duncan; Y Jia; E Soltesz; S Leung; H O Yilmaz; G Mao; A A Timur; K Kottke-Marchant; H J Rogers; C Ma; I Ince; N Karimi; S Yagar; C Trombetta; D I Sessler
Journal:  Anaesthesia       Date:  2020-02-18       Impact factor: 12.893

7.  Impact of 6% balanced hydroxyethyl starch following cardiopulmonary bypass on renal function: a retrospective study.

Authors:  Ju Yong Lim; Yun Seok Kim; Joon Bum Kim
Journal:  J Cardiothorac Surg       Date:  2020-09-07       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.